Symposium on Hidradenitis Suppurativa Advances (SHSA), 2024

Bimekizumab 2-Year Impact on HSSQ Skin Pain in Moderate to Severe HS: Data from BE HEARD EXT

Lauren A.V. Orenstein, Vivian Y. Shi, Lev-Tov Hadar, et al.

Bimekizumab 2-year Maintenance of Response in Moderate to Severe HS: Data from BE HEARD EXT

Martina L. Porter, Chovatiya Raj, Gulliver Wayne, et al.

Bimekizumab 2-year Efficacy by Prior Biologic Use in Moderate to Severe HS: Data from BE HEARD EXT

Vivian Y. Shi, Hsiao Jennifer, Christopher J Sayed, et al.

Bimekizumab Impact on Draining Tunnels Over 2 Years in HS: Data from BE HEARD EXT

Christos C Zouboulis, Hsiao Jennifer, Garg Amit, et al.

Bimekizumab 2-Year Impact on HSSQ Skin Pain in Moderate to Severe HS: Data from BE HEARD EXT

Lauren A.V. Orenstein, Vivian Y. Shi, Lev-Tov Hadar, et al.

Bimekizumab 2-year Impact on HS Symptoms by Baseline Draining Tunnel Count: Data from BE HEARD EXT

Christopher J Sayed, Martina L. Porter, Hamzavi Iltefat, et al.

Bimekizumab 2-Year Impact on HS Symptoms by Baseline Draining Tunnel Count: Data from BE HEARD EXT

Christopher J Sayed, Martina L. Porter, Hamzavi Iltefat, et al.